

Chemicals/Finland, May 2, 2022 Company update

Catching up with potential

Exel's EBIT appears bound to improve more from the recent lows. We make only minor revisions to our estimates.

Margins seem set to improve further during this year

Exel's Q1 revenue grew 10% y/y to EUR 34.2m, compared to the EUR 37.1m/33.9m Evli/cons. estimates. All industries continued to grow except Wind power and Defense, where timing issues led to 8% y/y top line declines but for which long-term outlook has clearly improved in the past few months. The latter remains relatively small but has a lot more potential in markets such as India, while we believe China's weakness also contributed to the decline of the former. Adj. EBIT amounted to EUR 2.2m vs the EUR 1.7m/1.4m Evli/cons. estimates. Product mix and variable cost inflation had a negative impact on profitability, masking some of the underlying positive development as Exel's pricing adjusts with a lag of few months. Energy costs are also up, but Exel should be able to pass them on as well; we note Exel can also adjust already signed orders' prices.

Guidance upgrade is much possible later this year

The US unit has now reached a break-even result; we estimate Exel's EBIT margin continues to improve towards 7% and beyond during this year. We estimate 7.5% margin for H2'22, a level previously seen in H1'21 but with the difference that this year top line will be 15% higher. The Chinese restructuring will also produce EUR 0.7m in annual cost synergies. China's virus situation pushed the Asia-Pacific region down 22% y/y in Q1; we believe there's a good chance Exel will revise guidance upwards later this year, especially if Chinese demand normalizes and productivity further progresses in the US.

Valuation appears very conservative

We estimate EUR 10.2m adj. EBIT for this year, on which Exel is valued about 11x. Exel has additional profitability potential beyond that and is valued 8x EV/EBIT on our FY '23 estimates. An 8.5% EBIT margin estimate doesn't seem to be too high for next year, considering Exel reached a higher margin in FY '20 while revenue will soon have grown by some 40% since then. There are no particularly relevant peers for Exel and hence valuation is a matter of judgment, but in our view Exel's earnings-based multiples appear very undemanding in the short and long-term perspective. Our new TP is EUR 8.5 (9); we retain our BUY rating.



Share price, EUR (Last trading day's closing price)	6.30
Target price, EUR	8.5
Latest change in recommendation	20-Jul-21
Latest report on company	16-Feb-22
Research paid by issuer:	YES
No. of shares outstanding, '000's	11,897
No. of shares fully diluted, '000's	11,897
Market cap, EURm	75
Free float, %	100.0
Exchange rate EUR/USD	1.06
Reuters code	EXL1V.HE
Bloomberg code	EXL1V FH
Average daily volume, EURm	0.2
Next interim report	20-Jul-22
Web site	www.exelcomposites.com
Analyst	Joonas Ilvonen
E-mail	joonas.ilvonen@evli.com
Telephone	+358 44 430 9071

■ BUY □ HOLD ■ SELL

KEY FIGU	RES										
	Sales EURm	EBIT EURm	EBIT %	FCF EURm	EPS EUR	P/E (x)	EV/Sales (x)	EV/EBIT (x)	FCF yield %	DPS EUR	
2020	108.6	9.4	8.7%	0.5	0.45	16.4	1.1	12.5	0.6	0.20	
2021	134.4	3.7	2.8%	-6.2	0.14	57.0	1.0	34.9	-6.5	0.20	
2022E	145.4	8.0	5.5%	3.9	0.49	12.9	8.0	13.7	5.2	0.25	
2023E	155.5	13.2	8.5%	7.2	0.77	8.2	0.7	8.0	9.6	0.30	
2024E	163.3	16.3	10.0%	10.4	1.01	6.3	0.6	6.0	13.9	0.32	
Market cap	, EURm		75 G	earing 2022E,	0/0		4, %	93.4			
Net debt 2	022E, EURm		35 Pi	35 Price/book 2022E			2.2 CAGR sales 2021-24, %				
Enterprise	value, EURm		110 D	110 Dividend yield 2022E, %			4.0 ROE 2022E, %				
Total assets	s 2022E, EURn	n	123 Ta	123 Tax rate 2022E, %			26.5 ROCE 2022E, %				
Goodwill 2	022E, EURm		13 Ec	quity ratio 202	22E, %		28.1 PEG, P	P/E 22/CAGR		0.4	



Chemicals/Finland, May 2, 2022 Company update

Estimates and peer group multiples

Exel Composites	2019	2020	Q1'21	Q2'21	Q3'21	Q4'21	2021	Q1'22	Q2'22e	Q3'22e	Q4'22e	2022e
Buildings and infrastructure	23.5	23.5	7.0	8.7	8.1	8.4	32.2	7.7	9.2	8.5	8.7	34.0
Equipment and other industries	18.6	19.5	5.6	5.2	5.4	7.1	23.4	7.4	6.1	6.0	7.6	27.1
Wind power	23.6	28.1	7.4	7.8	8.6	8.3	32.1	6.8	8.7	9.2	8.7	33.4
Machinery and electrical	14.4	15.5	3.6	5.1	4.8	4.9	18.4	4.3	5.3	5.1	5.1	19.7
Transportation	13.1	10.2	2.5	2.7	2.1	2.9	10.2	3.1	3.1	2.3	3.0	11.4
Defense	2.3	5.3	2.2	1.8	2.2	2.5	8.7	2.1	2.0	2.6	2.8	9.5
Telecommunications	8.2	6.5	2.5	2.3	2.3	2.3	9.5	2.8	2.4	2.4	2.4	10.1
Revenue	103.8	108.6	31.0	33.5	33.4	36.5	134.4	34.2	36.8	36.1	38.3	145.4
y/y change, %	7 %	5 %	11 %	23 %	28 %	33 %	24 %	10 %	10 %	8 %	5 %	8 %
Adjusted EBIT	7.2	9.7	2.5	2.5	0.1	1.0	6.0	2.2	2.4	2.6	3.0	10.2
EBIT	5.1	9.4	2.4	2.4	-1.7	0.6	3.7	0.0				8.0
-margin, %	6.9 %	8.9 %	7.9 %	7.3 %	0.3 %	2.8 %	4.5 %	6.4 %	6.5 %	7.2 %	7.8 %	7.0 %
-margin (reported), %	4.9 %	8.7 %	7.8 %	7.0 %	-5.1 %	1.8 %	2.8 %	0.1 %				5.5 %

	MCAP		EV/EBITDA			EV/EBIT			EBIT-%	
EXEL COMPOSITES PEER GF	MEUR	22	23	24	22	23	24	22	23	24
Gurit Holding	570	14.7x	12.0x	10.6x	20.8x	16.4x	14.3x	6.6 %	7.8 %	8.7 %
Hexagon Composites	753	35.4x	19.0x	13.3x		74.3x	48.4x	-1.5 %	2.2 %	2.2 %
Hexcel	4456	17.9x	13.9x	12.2x	33.5x	22.3x	18.5x	10.3 %	13.5 %	15.0 %
Avient	4372	9.5x	8.6x	8.5x	12.5x	11.1x	10.9x	9.4 %	10.0 %	10.9 %
SGL Carbon	639	6.8x	5.8x	5.1x	12.4x	9.6x	8.3x	6.9 %	8.5 %	9.2 %
TPI Composites	408	21.8x	7.6x	4.1x		21.2x	6.6x	-1.9 %	1.7 %	4.7 %
Peer Group Average	1866	17.7x	11.1x	9.0x	19.8x	25.8x	17.8x	5.0 %	7.3 %	8.4 %
Peer Group Median	696	16.3x	10.3x	9.5x	16.6x	18.8x	12.6x	6.7 %	8.1 %	8.9 %
Exel Composites (Evli est.)	75	7.8x	5.2x	4.2x	13.7x	8.0x	6.0x	5.5 %	8.5 %	10.0 %

-58 % Exel Composites prem./disc. to peer median -49 % -56 % 12 % -52 % -18 % -52 % -18 % 4 %

Source FactSet, Evli Research

Source: Evli Research

Chemicals/Finland, May 2, 2022 Company update

VALUATION RESULTS	BASE CASE DETAILS	VALUATION ASSUMPTIONS	ASSUMPTIONS FOR WACC	
Current share price	6.30 PV of Free Cash Flow	78 Long-term growth, %	1.5 Risk-free interest rate, %	2.25
DCF share value	11.89 PV of Horizon value	102 WACC, %	8.5 Market risk premium, %	5.8
Share price potential, %	88.8 Unconsolidated equity	O Spread, %	0.5 Debt risk premium, %	3.3
Maximum value	13.1 Marketable securities	16 Minimum WACC, %	8.0 Equity beta coefficient	1.00
Minimum value	10.8 Debt - dividend	-54 Maximum WACC, %	9.0 Target debt ratio, %	10
Horizon value, %	56.5 Value of stock	141 Nr of shares, Mn	11.9 Effective tax rate, %	21

DCF valuation, EURm	2021	2022E	2023E	2024E	2025E	2026E	2027E	2028E	2029E	2030E	2031E	Horizon
Net sales	134	145	156	163	168	172	176	179	183	187	189	192
Sales growth, %	23.7	8.2	7.0	5.0	3.0	2.5	2.0	2.0	2.0	2.0	1.5	1.5
Operating income (EBIT)	4	8	13	16	18	18	18	20	21	21	22	22
Operating income margin, %	2.8	5.5	8.5	10.0	10.5	10.5	10.5	11.0	11.5	11.5	11.5	11.5
+ Depreciation+amort.	8	6	7	7	7	7	7	7	7	7	7	
EBITDA	12	14	20	23	25	25	25	26	28	28	29	
- Paid taxes	-3	-2	-4	-4	-5	-5	-5	-5	-6	-6	-6	
- Change in NWC	- 5	-1	-1	-1	-1	-1	0	0	0	0	0	
NWC / Sales, %	<i>12.7</i>	12.7	12.8	12.8	12.9	12.9	12.9	12.9	12.9	12.9	12.9	
+ Change in other liabs	0	0	0	0	0	0	0	0	0	0	0	
- Operative CAPEX	-10	-6	-6	-6	-6	-7	-7	-7	-7	-7	-7	
opCAPEX / Sales, %	8.2	4.5	4.8	4.6	4.5	4.4	4.1	4.1	4.1	4.1	4.0	
- Acquisitions	0	0	0	0	0	0	0	0	0	0	0	
+ Divestments	0	0	0	0	0	0	0	0	0	0	0	
- Other items	0	0	0	0	0	0	0	0	0	0	0	
= FCFF	-5	4	9	12	13	13	13	14	15	15	16	225
= Discounted FCFF		4	8	9	10	9	8	8	8	7	7	102
= DFCF min WACC		4	8	9	10	9	8	8	8	8	7	115
= DFCF max WACC		4	8	9	9	9	8	8	8	7	7	91

Chemicals/Finland, May 2, 2022 Company update

INTERIM FIGURES

EVLI ESTIMATES, EURm	2021Q1	2021Q2	2021Q3	2021Q4	2021	2022Q1	2022Q2E	2022Q3E	2022Q4E	2022E	2023E	2024E
Net sales	31.0	33.5	33.4	36.5	134.4	34.2	36.8	36.1	38.3	145.4	155.5	163.3
EBITDA	4.0	3.9	0.0	4.1	11.9	1.3	4.0	4.2	4.6	14.1	20.1	23.3
EBITDA margin (%)	13.0	11.7	-0.1	11.1	8.9	3.9	10.8	11.6	12.0	9.7	12.9	14.3
EBIT	2.4	2.4	-1.7	0.6	3.7	0.0	2.4	2.6	3.0	8.0	13.2	16.3
EBIT margin (%)	7.8	7.0	-5.1	1.8	2.8	0.0	6.5	7.2	7.8	5.5	8.5	10.0
Net financial items	0.5	-0.5	0.4	0.0	0.4	0.5	-0.2	-0.2	-0.2	-0.1	-0.8	0.0
Pre-tax profit	2.9	1.9	-1.3	0.7	4.2	0.5	2.2	2.4	2.8	7.9	12.4	16.3
Tax	-0.9	-0.5	-0.9	-0.2	-2.5	-0.5	-0.5	-0.5	-0.6	-2.1	-3.3	-4.3
Tax rate (%)	30.8	25.4	-68.9	31.2	60.2	104.4	21.0	21.0	21.0	26.5	26.5	26.5
Net profit	2.0	1.4	-2.2	0.5	1.7	0.0	1.7	1.9	2.2	5.8	9.1	12.0
EPS	0.17	0.12	-0.19	0.04	0.14	0.00	0.15	0.16	0.19	0.49	0.77	1.01
EPS adjusted (diluted no. of shares)	0.17	0.12	-0.19	0.04	0.14	0.00	0.15	0.16	0.19	0.49	0.77	1.01
Dividend per share	0.00	0.00	0.00	0.00	0.20	0.00	0.00	0.00	0.00	0.25	0.30	0.32
SALES, EURm												
Exel Composites	31.0	33.5	33.4	36.5	134.4	34.2	36.8	36.1	38.3	145.4	155.5	163.3
Total	31.0	33.5	33.4	36.5	134.4	34.2	36.8	36.1	38.3	145.4	155.5	163.3
SALES GROWTH, Y/Y %												
Exel Composites	11.3	23.3	28.0	32.6	23.7	10.3	9.8	8.1	4.9	8.2	7.0	5.0
Total	11.3	23.3	28.0	32.6	23.7	10.3	9.8	8.1	4.9	8.2	7.0	5.0
EBIT, EURm												
Exel Composites	2.4	2.4	-1.7	0.6	3.7	0.0	2.4	2.6	3.0	8.0	13.2	16.3
Total	2.4	2.4	-1.7	0.6	3.7	0.0	2.4	2.6	3.0	8.0	13.2	16.3
EBIT margin, %										•	•	
Exel Composites	7.8	7.0	-5.1	1.8	2.8	0.1	6.5	7.2	7.8	5.5	8.5	10.0
Total	7.8	7.0	-5.1	1.8	2.8	0.1	6.5	7.2	7.8	5.5	8.5	10.0

Chemicals/Finland, May 2, 2022 Company update

INCOME STATEMENT, EURm	2017	2018	2019	2020	2021	2022E	2023E	2024E
Sales	86.3	96.6	103.8	108.6	134.4	145.4	155.5	163.3
Sales growth (%)	18.1	11.9	7.5	4.6	23.7	8.2	7.0	5.0
EBITDA	9.3	7.7	10.7	15.3	11.9	14.1	20.1	23.3
EBITDA margin (%)	10.8	8.0	10.3	14.1	8.9	9.7	12.9	14.3
Depreciation	-3.2	-5.5	-5.6	-5.8	-8.2	-6.1	-6.9	-7.0
EBITA	6.1	2.2	5.1	9.4	3.7	8.0	13.2	16.3
Goodwill amortization / writedown	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
EBIT	6.1	2.2	5.1	9.4	3.7	8.0	13.2	16.3
EBIT margin (%)	7.1	2.3	4.9	8.7	2.8	5.5	8.5	10.0
Reported EBIT	6.1	2.2	5.1	9.4	3.7	8.0	13.2	16.3
EBIT margin (reported) (%)	7.1	2.3	4.9	8.7	2.8	5.5	8.5	10.0
Net financials	-0.7	-0.5	-1.2	-2.3	0.4	-0.1	-0.8	0.0
Pre-tax profit	5.4	1.7	3.9	7.1	4.2	7.9	12.4	16.3
Taxes	-1.2	-1.3	-1.5	-1.7	-2.5	-2.1	-3.3	-4.3
Minority shares	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Net profit	4.2	0.4	2.4	5.4	1.7	5.8	9.1	12.0
Cash NRIs	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Non-cash NRIs	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
BALANCE SHEET, EURm								
Assets								
Fixed assets	16	21	23	30	34	34	34	35
Goodwill	13	13	13	13	13	13	13	13
Right of use assets	0	5	5	3	3	3	4	4
Inventory	12	15	17	16	24	26	28	29
Receivables	15	20	20	21	26	28	30	32
Liquid funds	8	5	7	12	16	17	18	19
Total assets	64	79	85	97	118	123	129	133
Liabilities								
Shareholder's equity	29	26	26	29	31	35	41	49
Minority interest	0	0	0	0	0	0	0	0
Convertibles	0	0	0	0	0	0	0	0
Lease liabilities	0	3	4	2	2	3	4	4
Deferred taxes	0	0	0	0	0	0	0	0
Interest bearing debt	16	30	32	40	50	48	45	39
Non-interest bearing current liabilities	18	18	21	24	32	35	37	39
Other interest-free debt	0	2	2	2	3	3	3	3
Total liabilities	64	79	85	97	118	123	129	133
CASH FLOW, EURm								
+ EBITDA	9	8	11	15	12	14	20	23
- Net financial items	-1	0	-1	-2	0	0	-1	0
- Taxes	-1	-2	-2	-2	-3	-2	-3	-4
- Increase in Net Working Capital	-3	-4	1	3	-5	-1	-1	-1
+/- Other	1	0	0	0	0	0	0	0
= Cash flow from operations	5	1	8	13	5	10	15	18
- Capex	-3	-10	-8	-13	-11	-6	-7	-8
- Acquisitions	0	0	0	0	0	0	0	0
+ Divestments	0	0	0	0	0	0 4	0 7	0
= Free cash flow	1	-9	1	0	-6			10
+/- New issues/buybacks	-1	0	0 -2	-1	3	0	0	0
- Paid dividend	-1 1	-4		-2 7	-2 9	-2 0	-3	-4
+/- Other	1 0	9 -3	3 2	7 5	9	1	-3 1	-6 1
Change in cash	U	-3	۷	Э	4	ı	ı	1

Chemicals/Finland, May 2, 2022 Company update

KEY FIGURES	2018	2019	2020	2021	2022E	2023E	2024E
M-cap	48	78	88	94	75	75	75
Net debt (excl. convertibles)	28	29	30	36	35	30	24
Enterprise value	76	107	118	131	110	105	99
Sales	97	104	109	134	145	156	163
EBITDA	8	11	15	12	14	20	23
EBIT	2	5	9	4	8	13	16
Pre-tax	2	4	7	4	8	12	16
Earnings	0	2	5	2	6	9	12
Equity book value (excl. minorities)	26	26	29	31	35	41	49
Valuation multiples							
EV/sales	0.8	1.0	1.1	1.0	0.8	0.7	0.6
EV/EBITDA	9.9	10.0	7.7	10.9	7.8	5.2	4.2
EV/EBITA	34.5	21.0	12.5	34.9	13.7	8.0	6.0
EV/EBIT	34.5	21.0	12.5	34.9	13.7	8.0	6.0
EV/OCF	84.3	12.9	8.8	27.2	10.5	7.2	5.5
EV/FCFF	-6.6	32.5	52.9	-26.0	25.8	11.8	8.6
P/FCFE	-5.5	110.9	179.1	-15.3	19.1	10.4	7.2
P/E	119.0	32.5	16.4	57.0	12.9	8.2	6.3
P/B	1.8	3.0	3.1	3.0	2.2	1.8	1.5
Target EV/EBITDA	0.0	0.0	0.0	0.0	9.6	6.5	5.3
Target EV/EBIT	0.0	0.0	0.0	0.0	16.9	10.0	7.6
Target EV/FCF	0.0	0.0	0.0	0.0	34.7	18.2	12.0
Target P/B	0.0	0.0	0.0	0.0	2.9	2.5	2.1
Target P/E	0.0	0.0	0.0	0.0	17.4	11.1	8.4
Per share measures							
Number of shares	11,897	11,897	11,897	11,897	11,897	11,897	11,897
Number of shares (diluted)	11,897	11,897	11,897	11,897	11,897	11,897	11,897
EPS	0.03	0.20	0.45	0.14	0.49	0.77	1.01
Operating cash flow per share	0.08	0.70	1.12	0.40	0.87	1.23	1.50
Free cash flow per share	-0.73	0.06	0.04	-0.52	0.33	0.61	0.87
Book value per share	2.16	2.21	2.41	2.62	2.91	3.43	4.14
Dividend per share	0.18	0.18	0.20	0.20	0.25	0.30	0.32
Dividend payout ratio, %	535.4	89.2	44.3	143.7	51.1	39.1	31.8
Dividend yield, %	4.5	2.7	2.7	2.5	4.0	4.8	5.1
FCF yield, %	-18.3	0.9	0.6	-6.5	5.2	9.6	13.9
Efficiency measures					-		
ROE	1.5	9.2	19.5	5.5	17.7	24.2	26.6
ROCE	4.5	8.6	14.4	5.1	9.7	13.7	18.3
Financial ratios		0.0		0	0.7		10.0
Inventories as % of sales	15.7	16.3	14.9	17.8	17.8	17.8	17.8
Receivables as % of sales							
	20.8	19.2	19.2	19.6	19.6	19.6	19.6
Non-interest hearing liabilities as % of sales	20.8 19.2	19.2 20.2	19.2 22.0	19.6 23.8	19.6 23.8	19.6 23.8	19.6 23.8
Non-interest bearing liabilities as % of sales NWC/sales %	19.2	20.2	22.0	23.8	23.8	23.8	23.8
NWC/sales, %	19.2 16.1	20.2 14.1	22.0 11.2	23.8 12.7	23.8 12.7	23.8 12.8	23.8 12.8
NWC/sales, % Operative CAPEX/sales, %	19.2 16.1 9.9	20.2 14.1 7.3	22.0 11.2 11.9	23.8 12.7 8.2	23.8 12.7 4.5	23.8 12.8 4.8	23.8 12.8 4.6
NWC/sales, % Operative CAPEX/sales, % CAPEX/sales (incl. acquisitions), %	19.2 16.1 9.9 9.9	20.2 14.1 7.3 7.3	22.0 11.2 11.9 11.9	23.8 12.7 8.2 8.2	23.8 12.7 4.5 4.5	23.8 12.8 4.8 4.8	23.8 12.8 4.6 4.6
NWC/sales, % Operative CAPEX/sales, % CAPEX/sales (incl. acquisitions), % FCFF/EBITDA	19.2 16.1 9.9 9.9 -1.5	20.2 14.1 7.3 7.3 0.3	22.0 11.2 11.9 11.9 0.1	23.8 12.7 8.2 8.2 -0.4	23.8 12.7 4.5 4.5 0.3	23.8 12.8 4.8 4.8 0.4	23.8 12.8 4.6 4.6 0.5
NWC/sales, % Operative CAPEX/sales, % CAPEX/sales (incl. acquisitions), % FCFF/EBITDA Net debt/EBITDA, book-weighted	19.2 16.1 9.9 9.9 -1.5 3.7	20.2 14.1 7.3 7.3 0.3 2.7	22.0 11.2 11.9 11.9 0.1 2.0	23.8 12.7 8.2 8.2 -0.4 3.0	23.8 12.7 4.5 4.5 0.3 2.5	23.8 12.8 4.8 4.8 0.4 1.5	23.8 12.8 4.6 4.6 0.5 1.0
NWC/sales, % Operative CAPEX/sales, % CAPEX/sales (incl. acquisitions), % FCFF/EBITDA Net debt/EBITDA, book-weighted Debt/equity, market-weighted	19.2 16.1 9.9 9.9 -1.5 3.7 0.6	20.2 14.1 7.3 7.3 0.3 2.7 0.4	22.0 11.2 11.9 11.9 0.1 2.0 0.5	23.8 12.7 8.2 8.2 -0.4 3.0 0.5	23.8 12.7 4.5 4.5 0.3 2.5 0.6	23.8 12.8 4.8 4.8 0.4 1.5	23.8 12.8 4.6 4.6 0.5 1.0
NWC/sales, % Operative CAPEX/sales, % CAPEX/sales (incl. acquisitions), % FCFF/EBITDA Net debt/EBITDA, book-weighted	19.2 16.1 9.9 9.9 -1.5 3.7	20.2 14.1 7.3 7.3 0.3 2.7	22.0 11.2 11.9 11.9 0.1 2.0	23.8 12.7 8.2 8.2 -0.4 3.0	23.8 12.7 4.5 4.5 0.3 2.5	23.8 12.8 4.8 4.8 0.4 1.5	23.8 12.8 4.6 4.6 0.5 1.0

EVLI EQUITY RESEARCH

EXEL COMPOSITES

Chemicals/Finland, May 2, 2022 Company update

COMPANY DESCRIPTION: Exel Composites manufactures composites profiles for various demanding, mainly industrial end-use, applications. Exel's customer base includes companies operating in industries such as wind energy, transportation and telecommunications. Exel Composites is one of the largest manufacturers of pultruded composites profiles globally and currently operates eight manufacturing plants on three continents.

INVESTMENT CASE: Our positive view is based on good long-term composites demand outlook, coupled with the fact that Exel Composites' current manufacturing footprint could support annual revenue in the EUR 150m ballpark i.e. there's still plenty of room to improve delivery volumes. Exel's rather high fixed cost base translates to meaningful operating leverage, and thus higher revenues should lead to improving operating margins. The company is also progressing well with its cost savings program. Operating profit could further significantly improve if good execution continues. Recently the wind energy sector has provided great lift for volumes; other attractive applications include e.g. transportation industry profiles.

OWNERSHIP STRUCTURE	SHARES	EURm	0/0
Sijoitusrahasto Taaleritehdas Mikro Markka	800,000	5.040	6.7%
OP-Finland Small Firms Fund	590,119	3.718	5.0%
Op-Suomi Mikroyhtiöt -Erikoissijoitusrahasto	420,000	2.646	3.5%
Ilmarinen Mutual Pension Insurance	392,733	2.474	3.3%
Phoebus Fund	350,000	2.205	2.9%
Säästöpankki Pienyhtiöt	288,710	1.819	2.4%
Veritas Pension Insurance Company Ltd.	224,261	1.413	1.9%
Nelimarkka Heikki Antero	213,545	1.345	1.8%
Matti Suutarinen	198,000	1.247	1.7%
Säästöpankki Kotimaa	132,680	0.836	1.1%
Ten largest	3,610,048	22.743	30%
Residual	8,286,795	52.207	70%
Total	11,896,843	74.950	100%

EARNINGS CALENDAR	
July 20, 2022	Q2 report
November 03, 2022	Q3 report
OTHER EVENTS	

COMPANY N	IISCELLANEOUS
-----------	----------------------

CEO: Riku Kytömäki CFO: Mikko Kettunen IR: Noora Koikkalainen Mäkituvantie 5 01510 Vantaa Tel: +358 20 7541 200

Chemicals/Finland, May 2, 2022 Company update

DEFINITIONS

P/E	EPS	
170	LIJ	
Price per share Earnings per share	Profit before extraord. items and taxes- income taxes + minority interest Number of shares	
P/BV	DPS	
Price per share Shareholders' equity + taxed provisions per share	Dividend for the financial period per share	
Market cap	OCF (Operating cash flow)	
Price per share * Number of shares	EBITDA – Net financial items – Taxes – Increase in working capital – Cash NRIs ± Other adjustments	
EV (Enterprise value)	FCF (Free cash flow)	
Market cap + net debt + minority interest at market value – share of associated companies at market value	Operating cash flow – operative CAPEX – acquisitions + divestments	
EV/Sales	FCF yield, %	
Enterprise value Sales	<u>Free cash flow</u> Market cap	
EV/EBITDA	Operative CAPEX/sales	
Enterprise value Earnings before interest, tax, depreciation and amortization	Capital expenditure – divestments – acquisitions Sales	
EV/EBIT	Net working capital	
Enterprise value Operating profit	Current assets – current liabilities	
Net debt	Capital employed/Share	
Interest bearing debt – financial assets	Total assets – non-interest bearing debt Number of shares	
Total assets	Gearing	
Balance sheet total	<u>Net debt</u> Equity	
Div yield, %	Debt/Equity, %	
Dividend per share Price per share	Interest bearing debt Shareholders' equity + minority interest + taxed provisions	
Payout ratio, %	Equity ratio, %	
Total dividends Earnings before extraordinary items and taxes – income taxes + minority interest	Shareholders' equity + minority interest + taxed provisions Total assets – interest-free loans	
ROCE, %	CAGR, %	
Profit before extraordinary items + interest expenses+ other financial costs Balance sheet total – non-interest bearing debt (average)	Cumulative annual growth rate = Average growth per year	
ROE, %		
Profit before extraordinary items and taxes – income taxes Shareholder's equity + minority interest + taxed provisions (average)		

Chemicals/Finland, May 2, 2022 Company update

Important Disclosures


Evli Research Partners Plc ("ERP") uses 12-month target prices. Target prices are defined by utilizing analytical techniques based on financial theory including (but not limited to) discounted cash flow analysis and comparative valuation. The selection of valuation methods depends on different circumstances. Target prices may be altered on the basis of new information coming to light in the underlying company or changes in interest rates, changes in foreign exchange rates, other securities prices or market indices or outlook for the aforementioned factors or other factors that may change the conditions of financial markets. Recommendations and changes by analysts are available at <u>Analysts' recommendations and ratings revisions</u>.

Investment recommendations are defined as follows:

Target price compared to share price Recommendation

< -10 % SELL -10 - (+10) % HOLD > 10 % BUY

ERP's investment recommendation of the analyzed company is updated at least 2 times per year.



The graph above shows the distribution of ERP's recommendations of companies under coverage in 11th of May 2020. If recommendation is not given, it is not mentioned here.

Name(s) of the analyst(s): Ilvonen

This research report has been prepared by Evli Research Partners Plc ("ERP" or "Evli Research"). ERP is a subsidiary of Evli Bank Plc. Production of the investment recommendation has been concluded on [2.5.2022, 8:45]. This report has been published on [2.5.2022, 9:00].

None of the analysts contributing to this report, persons under their guardianship or corporations under their control have a position in the shares of the company or related securities.

The date and time for any price of financial instruments mentioned in the recommendation refer to the previous trading day's closing price(s) unless otherwise stated in the report.

Each analyst responsible for the content of this report assures that the expressed views accurately reflect the personal views of each analyst on the covered companies and securities. Each analyst assures that (s)he has not been, nor are or will be, receiving direct or indirect compensation related to the specific recommendations or views contained in this report.

Companies in the Evli Group, affiliates or staff of companies in the Evli Group, may perform services for, solicit business from, hold long or short positions in, or otherwise be interested in the investments (including derivatives) of any company mentioned in the publication or report.

Neither ERP nor any company within the Evli Group have managed or co-managed a public offering of the company's securities during the last 12 months prior to, received compensation for investment banking services from the company during the last 12 months prior to the publication of the research report.

ERP has signed an agreement with the issuer of the financial instruments mentioned in the recommendation, which includes production of research reports. This assignment has a limited economic and financial impact on ERP and/or Evli. Under the assignment ERP performs services including, but not limited to, arranging investor meetings or –events, investor relations communication advisory and production of research material.

ERP or another company within the Evli Group does not have an agreement with the company to perform market making or liquidity providing services.

For the prevention and avoidance of conflicts of interests with respect to this report, there is an information barrier (Chinese wall) between Investment

EVLI EQUITY RESEARCH

EXEL COMPOSITES

Chemicals/Finland, May 2, 2022 Company update

Research and Corporate Finance units concerning unpublished investment banking services to the company. The remuneration of the analyst(s) is not tied directly or indirectly to investment banking transactions or other services performed by Evli Bank Plc or any company within Evli Group.

This report has not been disclosed to the company prior to its dissemination.

This report is provided and intended for informational purposes only and may not be used or considered under any circumstances as an offer to sell or buy any securities or as advice to trade any securities.

This report is based on sources ERP considers to be correct and reliable. The sources include information providers Reuters and Bloomberg, stock-exchange releases from the companies and other company news, Statistics Finland and articles in newspapers and magazines. However, ERP does not guarantee the materialization, correctness, accuracy or completeness of the information, opinions, estimates or forecasts expressed or implied in the report. In addition, circumstantial changes may have an influence on opinions and estimates presented in this report. The opinions and estimates presented are valid at the moment of their publication and they can be changed without a separate announcement. Neither ERP nor any company within the Evli Group are responsible for amending, correcting or updating any information, opinions or estimates contained in this report. Neither ERP nor any company within the Evli Group will compensate any direct or consequential loss caused by or derived from the use of the information represented in this publication.

All information published in this report is for the original recipient's private and internal use only. ERP reserves all rights to the report. No part of this publication may be reproduced or transmitted in any form or by any means, electronic, mechanical, photocopying, recording or otherwise, or stored in any retrieval system of any nature, without the written permission of ERP.

This report or its copy may not be published or distributed in Australia, Canada, Hong Kong, Japan, New Zealand, Singapore or South Africa. The publication or distribution of this report in certain other jurisdictions may also be restricted by law. Persons into whose possession this report comes are required to inform themselves about and to observe any such restrictions.

Evli Bank Plc is not registered as a broker-dealer with the U. S. Securities and Exchange Commission ("SEC"), and it and its analysts are not subject to SEC rules on securities analysts' certification as to the currency of their views reflected in the research report. Evli Bank is not a member of the Financial Industry Regulatory Authority ("FINRA"). It and its securities analysts are not subject to FINRA's rules on Communications with the Public and Research Analysts and Research Reports and the attendant requirements for fairness, balance and disclosure of potential conflicts of interest. This research report is only being offered in U.S. by Auerbach Grayson & Company, LLC (Auerbach Grayson) to Major U.S. Institutional Investors and is not available to, and should not be used by, any U.S. person or entity that is not a Major U.S. Institutional Investor. Auerbach Grayson is a broker-dealer registered with the U.S. Securities and Exchange Commission and is a member of the FINRA. U.S. entities seeking more information about any of the issuers or securities discussed in this report should contact Auerbach Grayson. The securities of non-U.S. issuers may not be registered with or subject to SEC reporting and other requirements.

ERP is not a supervised entity but its parent company Evli Bank Plc is supervised by the Finnish Financial Supervision Authority.

Chemicals/Finland, May 2, 2022 Company update

Contact information SALES, TRADING AND RESEARCH

Equity, ETF and Derivatives Sales		Trading	
Joachim Dannberg Ari Laine Kimmo Lilja	+358 9 4766 9123 +358 9 4766 9115 +358 9 4766 9130	Lauri Vehkaluoto (Head) Pasi Väisänen Antti Kässi Miika Ronkanen	+358 9 4766 9120 +358 9 4766 9120 +358 9 4766 9120 +358 9 4766 9120
Structured Investments		Equity Research	
Heikki Savijoki Aki Lakkisto	+358 9 4766 9726 +358 9 4766 9123	Jonas Forslund Joonas Ilvonen Jerker Salokivi Teemu Reiman	+358 9 4766 9314 +358 44 430 9071 +358 9 4766 9149 +358 40 352 6175
Evli Investment Solutions			
Johannes Asuja	+358 9 4766 9205		



EVLI BANK PLC
Aleksanterinkatu 19 A
P.O. Box 1081
FIN-00101 Helsinki, FINLAND
Phone +358 9 476 690
Fax +358 9 634 382
Internet www.evli.com
E-mail firstname.lastname@evli.com

EVLI BANK PLC, STOCKHOLMSFILIAL Regeringsgatan 67 P.O. Box 16354 SE-103 26 Stockholm Sverige stockholm@evli.com Tel +46 (0)8 407 8000 Fax +46 (0)8 407 8001